Gastroesophageal reflux disease: clinical features
- PMID: 16341946
- DOI: 10.1007/s11096-005-7116-5
Gastroesophageal reflux disease: clinical features
Abstract
Gastroesophageal reflux disease (GERD) is a chronic disease affecting up to 40% of people in the Western world. Risk factors associated with GERD include age and lifestyle habits, although the clinically relevant contribution of many of these factors is unclear. In GERD, refluxed gastric acid damages the oesophageal mucosa, generally when the pH falls below 4. GERD patients present a variety of symptoms, most commonly heartburn and regurgitation. Oesophageal complications associated with GERD include erosions, ulcers, peptic strictures, and Barrett's oesophagus which is implicated in the development of oesophageal adenocarcinoma. Diagnosis of GERD is problematic due to the range of symptoms which may be presented to the physician and symptom severity is frequently unrelated to disease severity. While endoscopic monitoring may be used to assess the presence and severity of GERD, a lack of visible damage does not necessarily indicate an absence of GERD. Techniques used to diagnose GERD include addition of an acid solution into the oesophagus in order to replicate symptoms (Bernstein test) or 24-hour intra-oesophageal pH monitoring. Proton pump inhibitors are effective in the treatment of GERD, acting to reduce the acidity of the gastric juice and hence reduce oesophageal damage and symptoms associated with GERD. Symptoms most indicative of GERD are those associated with erosive oesophagitis, including heartburn and acid regurgitation. Less common GERD-associated symptoms include chest pain, a range of ear, nose and throat conditions, and asthma. In contrast to perceptions of the disease as 'merely' heartburn, the impact on patients' quality of life can be profound. Increasing awareness of GERD by health care professionals has led to improved diagnosis and a greater appreciation of the need for maintenance therapy.
Comment on
-
Treatment of gastroesophageal reflux disease.Pharm World Sci. 2005 Dec;27(6):432-5. doi: 10.1007/s11096-005-4798-7. Pharm World Sci. 2005. PMID: 16341949 Review.
Similar articles
-
Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.Dis Esophagus. 2013 Jul;26(5):443-50. doi: 10.1111/j.1442-2050.2012.01381.x. Epub 2012 Aug 2. Dis Esophagus. 2013. PMID: 22862422
-
Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?Aliment Pharmacol Ther. 2004 Feb;19 Suppl 1:28-34. doi: 10.1111/j.0953-0673.2004.01835.x. Aliment Pharmacol Ther. 2004. PMID: 14725576 Review.
-
Gastroesophageal reflux disease: clinical manifestations.Gastroenterol Nurs. 2003 Sep-Oct;26(5):195-200. doi: 10.1097/00001610-200309000-00005. Gastroenterol Nurs. 2003. PMID: 14603078 Review.
-
Clinical manifestations and complications of gastroesophageal reflux disease (GERD).Int J Clin Pract. 2005 Mar;59(3):346-55. doi: 10.1111/j.1742-1241.2005.00370.x. Int J Clin Pract. 2005. PMID: 15857335 Review.
-
The clinical characteristics of gastroesophageal reflux disease in patients with laryngeal symptoms who are referred to gastroenterology.Dis Esophagus. 2013 Jul;26(5):465-9. doi: 10.1111/j.1442-2050.2012.01375.x. Epub 2012 Jul 20. Dis Esophagus. 2013. PMID: 22816650
Cited by
-
Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus.J Hum Genet. 2007;52(6):527-534. doi: 10.1007/s10038-007-0148-z. Epub 2007 May 3. J Hum Genet. 2007. PMID: 17476458
-
P2 receptors signaling in the esophagus: from inflammation to cancer.Purinergic Signal. 2025 May 8. doi: 10.1007/s11302-025-10089-4. Online ahead of print. Purinergic Signal. 2025. PMID: 40338451 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical